News Image

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Provided By GlobeNewswire

Last update: Apr 7, 2025

ZUG, Switzerland, April 07, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.

Read more at globenewswire.com

PHARVARIS NV

NASDAQ:PHVS (7/25/2025, 8:16:51 PM)

20.62

+0.57 (+2.84%)



Find more stocks in the Stock Screener

Follow ChartMill for more